← Leaderboards
Jessica Rose Spires
Case Western Reserve University
$1,415,940
Attributed
$1,665,940
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $430K · FY2009–24$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
FDA$1,503,440 · 3
NIH$162,500 · 1
By mechanism
U01$1,503,440 · 3
F31$162,500 · 1
Top collaborators
- Manas Shah2 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Marni J Falk$11,808,270
- Francisco H Andrade$4,641,776
- Jacob E Friedman$21,580,959
- Jianjie Ma$31,916,684
- Joseph Charles Lamanna$8,812,514
Others in their field
Top investigators on “1,5-Dihydro-Fad”
- Christopher T Walsh · Dana-Farber Cancer Institute$2,918,751
- P. Andy Li · University Of Hawaii At Manoa$1,154,275
- Adrie Jc Steyn · University Of Alabama At Birmingham$1,087,764
- Navdeep S. Chandel · Northwestern University$837,130
- Raimond Lester Winslow · Johns Hopkins University$756,824
- Natalia A. Trayanova · Johns Hopkins University$756,824
Research focus
1,5-Dihydro-FadAffectAgingAdenylateAnimalsCanis FamiliarisCell RespirationChronicCitric Acid CycleAnimal ExperimentsComplexComputer SimulationConsumptionCystic FibrosisDiabetes MellitusDiagnosticElectronicsEnergy MetabolismEnergy TransferEnzyme ActivityExerciseFatty Acid OxidationGenerationsGlycolysis Pathway
Grant awards (12)
Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human$100,000
U01 · FY2024 · FD · contact PI
Dermal Drug Product Quality and Bioequivalence Assessment through Advanced MAM and PBPK Simulation$250,000
U01 · FY2022 · FD · contact PI
Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human$40,000
U01 · FY2022 · FD · contact PI
Dermal Drug Product Quality and Bioequivalence Assessment through Advanced MAM and PBPK Simulation$250,000
U01 · FY2021 · FD · contact PI
Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human$180,000
U01 · FY2021 · FD · contact PI
Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human$180,000
U01 · FY2020 · FD · contact PI
Assessment of Transdermal Drug Product Quality and Performance Attributes via Enhanced Virtual Bioequivalence Simulations$250,000
U01 · FY2019 · FD · contact PI
Assessment of Transdermal Drug Product Quality and Performance Attributes via Enhanced Virtual Bioequivalence Simulations$253,440
U01 · FY2018 · FD · contact PI
Mechamism of Activation of Oxidative Metabolism in vivo During Exercise$41,210
F31 · FY2012 · GM · contact PI
Mechamism of Activation of Oxidative Metabolism in vivo During Exercise$40,778
F31 · FY2011 · GM · contact PI
Mechamism of Activation of Oxidative Metabolism in vivo During Exercise$40,358
F31 · FY2010 · GM · contact PI
Mechamism of Activation of Oxidative Metabolism in vivo During Exercise$40,154
F31 · FY2009 · GM · contact PI